News

Deal Announcements

Arsanis Closes Series B Venture Capital Round

Wednesday, September 4, 2013 5:29:00 AM PDT | VentureDeal
Lebanon, New Hampshire  --  Biotechnology company Arsanis has secured $20 million in its second institutional venture capital investment financing.

Arsanis is developing fully human monoclonal antibodies against severe infectious diseases.

NeoMed Management led the round, which included previous investors OrbiMed Advisors, Polaris Partners and SV Life Sciences.

The company said it would use the funds to focus on its ASN-100 candidate against Staphylococcus aureus.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1